Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

2.980 +0.160 (+5.67%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	190,656
Open	2.920
Bid (Size)	2.820 (200)
Ask (Size)	3.000 (400)
Prev. Close	2.820
Today's Range	2.712 - 3.200
52wk Range	2.530 - 395.98
Shares Outstanding	171,350,166
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

May 06, 2026

Via ACCESS Newswire

These stocks are moving in today's session ↗

May 04, 2026

Via Chartmill

Performance

YTD	-91.5%	-91.5%
1 Month	-79.2%	-79.2%
3 Month	-85.6%	-85.6%
6 Month	-95.0%	-95.0%
1 Year	-99.2%	-99.2%

More News

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

May 04, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Monday's session. ↗

May 04, 2026

Via Chartmill

Jaguar Health Reports 2025 Financials

April 07, 2026

Via ACCESS Newswire

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

May 04, 2026

Via ACCESS Newswire

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

April 29, 2026

Via ACCESS Newswire

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

April 27, 2026

Via ACCESS Newswire

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

April 24, 2026

Via ACCESS Newswire

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

April 20, 2026

Via ACCESS Newswire

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

April 13, 2026

Via ACCESS Newswire

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

April 09, 2026

Via ACCESS Newswire

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

April 02, 2026

Via ACCESS Newswire

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

March 18, 2026

Via ACCESS Newswire

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

March 16, 2026

Via ACCESS Newswire

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

March 13, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

March 11, 2026

Via ACCESS Newswire

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

March 10, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

March 09, 2026

Via ACCESS Newswire

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

March 03, 2026

Via ACCESS Newswire

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

March 02, 2026

Via ACCESS Newswire

Jaguar Health Announces a Special One-time Stock Dividend

February 18, 2026

Via ACCESS Newswire

Monday's after hours session: top gainers and losers ↗

February 09, 2026

Via Chartmill

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

January 22, 2026

Via ACCESS Newswire

Here are the top movers in Tuesday's session. ↗

January 20, 2026

Via Chartmill

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?

Yes, Jaguar Health, Inc. - Common Stock is publicly traded.

What exchange does Jaguar Health, Inc. - Common Stock trade on?

Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jaguar Health, Inc. - Common Stock?

The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market

What is the current price of Jaguar Health, Inc. - Common Stock?

The current price of Jaguar Health, Inc. - Common Stock is 2.980

When was Jaguar Health, Inc. - Common Stock last traded?

The last trade of Jaguar Health, Inc. - Common Stock was at 05/07/26 04:00 PM ET

What is the market capitalization of Jaguar Health, Inc. - Common Stock?

The market capitalization of Jaguar Health, Inc. - Common Stock is 510.62M

How many shares of Jaguar Health, Inc. - Common Stock are outstanding?

Jaguar Health, Inc. - Common Stock has 511M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.